Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 43, 45, 1, 3, 54, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 6, 8 and 7 molecules, respectively.Chronic Lymphocytic Leukemia (CLL).
Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG
AbbVie Inc
Acetylon Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Altor BioScience Corp
Amgen Inc
Aprea AB
Aptevo Therapeutics Inc
Arno Therapeutics Inc
ArQule Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
Baliopharm AG
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Biogen Inc
Bionomics Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
Cellectis SA
Cellular Biomedicine Group Inc
Coherus BioSciences Inc
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GeneaMed Ltd
Genentech Inc
Genor BioPharma Co Ltd
Gilead Sciences Inc
Grupo Ferrer Internacional SA
Hutchison MediPharma Ltd
Hybrigenics SA
Igenica Biotherapeutics Inc
Immatics Biotechnologies GmbH
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Inflection Biosciences Ltd
Innate Pharma SA
Innovent Biologics Inc
Johnson & Johnson
Juno Therapeutics Inc
Kancera AB
Karyopharm Therapeutics Inc
Kite Pharma Inc
Les Laboratoires Servier SAS
LFB SA
Lymphocyte Activation Technologies SA
Medicenna Therapeutics Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MorphoSys AG
NantKwest Inc
Nordic Nanovector ASA
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co Ltd
Panacea Biotec Ltd
PEP-Therapy SAS
Pfizer Inc
Pharmacyclics Inc
PIQUR Therapeutics AG
Portola Pharmaceuticals Inc
Redx Pharma Plc
Respiratorius AB
Revitope Oncology, Inc.
Rhizen Pharmaceuticals SA
Sandoz International GmbH
Sanofi
Selvita SA
Simcere Pharmaceutical Group
Sorrento Therapeutics Inc
Supratek Pharma Inc
Takeda Pharmaceutical Company Ltd
Targazyme Inc
TG Therapeutics Inc
The International Biotechnology Center (IBC) Generium
Theravectys SA
Tolero Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
Trillium Therapeutics Inc
United BioPharma, Inc.
Unum Therapeutics Inc
Verastem Inc
VioQuest Pharmaceuticals Inc
Viralytics Ltd
Xencor Inc
ZIOPHARM Oncology Inc
Zymeworks Inc
'
Table of Contents
Table of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 20
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 22
Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 26
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 40
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 42
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 141
Drug Profiles 168
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 713
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 726
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 728
Appendix 745
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2016 30
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 31
Number of Products under Development by Companies, H2 2016 33
Number of Products under Development by Companies, H2 2016 (Contd..1) 34
Number of Products under Development by Companies, H2 2016 (Contd..2) 35
Number of Products under Development by Companies, H2 2016 (Contd..3) 36
Number of Products under Development by Companies, H2 2016 (Contd..4) 37
Number of Products under Development by Companies, H2 2016 (Contd..5) 38
Number of Products under Development by Companies, H2 2016 (Contd..6) 39
Number of Products under Development by Companies, H2 2016 (Contd..7) 40
Number of Products under Investigation by Universities/Institutes, H2 2016 42
Comparative Analysis by Late Stage Development, H2 2016 43
Comparative Analysis by Clinical Stage Development, H2 2016 44
Comparative Analysis by Early Stage Development, H2 2016 45
Comparative Analysis by Unknown Stage Development, H2 2016 46
Products under Development by Companies, H2 2016 47
Products under Development by Companies, H2 2016 (Contd..1) 48
Products under Development by Companies, H2 2016 (Contd..2) 49
Products under Development by Companies, H2 2016 (Contd..3) 50
Products under Development by Companies, H2 2016 (Contd..4) 51
Products under Development by Companies, H2 2016 (Contd..5) 52
Products under Development by Companies, H2 2016 (Contd..6) 53
Products under Development by Companies, H2 2016 (Contd..7) 54
Products under Development by Companies, H2 2016 (Contd..8) 55
Products under Development by Companies, H2 2016 (Contd..9) 56
Products under Development by Companies, H2 2016 (Contd..10) 57
Products under Development by Companies, H2 2016 (Contd..11) 58
Products under Development by Companies, H2 2016 (Contd..12) 59
Products under Development by Companies, H2 2016 (Contd..13) 60
Products under Investigation by Universities/Institutes, H2 2016 61
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 62
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016 63
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016 64
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 65
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 66
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H2 2016 67
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H2 2016 68
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprea AB, H2 2016 69
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2016 70
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H2 2016 71
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H2 2016 72
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H2 2016 73
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 74
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H2 2016 75
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2016 76
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H2 2016 77
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 78
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen Inc, H2 2016 79
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H2 2016 80
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H2 2016 81
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H2 2016 82
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 83
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016 84
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H2 2016 85
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis SA, H2 2016 86
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 87
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H2 2016 88
Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H2 2016 89
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 90
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 91
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H2 2016 92
Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93
Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H2 2016 94
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H2 2016 95
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co Ltd, H2 2016 96
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H2 2016 97
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H2 2016 98
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H2 2016 99
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H2 2016 100
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H2 2016 101
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 102
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen Inc, H2 2016 103
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H2 2016 104
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H2 2016 105
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H2 2016 106
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2016 107
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H2 2016 108
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2016 109
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H2 2016 110
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2016 111
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 112
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H2 2016 113
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2016 114
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H2 2016 115
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H2 2016 116
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Inc, H2 2016 117
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H2 2016 118
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H2 2016 119
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2016 120
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mesoblast Ltd, H2 2016 121
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 122
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016 123
Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H2 2016 124
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Nordic Nanovector ASA, H2 2016 125
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016 126
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 127
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 128
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Ltd, H2 2016 129
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H2 2016 130
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H2 2016 131
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics Inc, H2 2016 132
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H2 2016 133
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals Inc, H2 2016 134
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H2 2016 135
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2016 136
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Revitope Oncology, Inc., H2 2016 137
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 138
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H2 2016 139
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016 140
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H2 2016 141
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H2 2016 142
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H2 2016 143
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H2 2016 144
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 145
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H2 2016 146
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H2 2016 147
Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 148
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H2 2016 149
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 150
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 151
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 152
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H2 2016 153
Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma, Inc., H2 2016 154
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H2 2016 155
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H2 2016 156
Chronic Lymphocytic Leukemia (CLL) - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 157
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H2 2016 158
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H2 2016 159
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H2 2016 160
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc, H2 2016 161
Assessment by Monotherapy Products, H2 2016 162
Assessment by Combination Products, H2 2016 163
Number of Products by Stage and Target, H2 2016 165
Number of Products by Stage and Mechanism of Action, H2 2016 175
Number of Products by Stage and Route of Administration, H2 2016 186
Number of Products by Stage and Molecule Type, H2 2016 188
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016 734
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016 735
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H2 2016 736
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H2 2016 737
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H2 2016 738
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H2 2016 739
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H2 2016 740
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H2 2016 741
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H2 2016 742
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H2 2016 743
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..10), H2 2016 744
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..11), H2 2016 745
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..12), H2 2016 746
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016 747
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H2 2016 748
List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2016 30
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 31
Number of Products under Development by Companies, H2 2016 32
Number of Products under Investigation by Universities/Institutes, H2 2016 41
Comparative Analysis by Late Stage Development, H2 2016 43
Comparative Analysis by Clinical Stage Development, H2 2016 44
Comparative Analysis by Early Stage Products, H2 2016 45
Assessment by Monotherapy Products, H2 2016 162
Assessment by Combination Products, H2 2016 163
Number of Products by Top 10 Targets, H2 2016 164
Number of Products by Stage and Top 10 Targets, H2 2016 164
Number of Products by Top 10 Mechanism of Actions, H2 2016 174
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 174
Number of Products by Routes of Administration, H2 2016 185
Number of Products by Stage and Routes of Administration, H2 2016 185
Number of Products by Top 10 Molecule Types, H2 2016 187
Number of Products by Stage and Top 10 Molecule Types, H2 2016 187
